News | Webinars | Publications | Conferences | Upcoming Events |
Serotonin receptor 1A knockout: an animal model of anxiety-related disorder.
Monitoring chemistry of brain microenvironment: biosensors, microdialysis and related techniques.
Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor.
The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics Psychopharmacology (Berl)
Pharmacology of Temporal Cognition in Two Mouse Strains.
Timing and Foraging: Gibbon’s Scalar Expectancy Theory and Optimal Patch Exploitation.
Mark Hofer Esq. Joins PsychoGenics as General Counsel
Neuregulin 1 and susceptibility to schizophrenia.
In need of high-throughput behavioral systems.
PsychoGenics Obtains Funding For Their High Throughput CNS Drug Discovery Platform
Stress-induced hyperthermia and anxiety: pharmacological validation.
Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats.
Striatal plasticity at the network level. Focus on adenosine A(2A) and D(2) interactions in models of Parkinson’s Disease.
Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain.
Juvenile 5HT(1B) receptor knockout mice exhibit reduced pharmacological sensitivity to 5HT(1A) receptor activation.
Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice.
PsychoGenics Names Paul McGonigle Chief Scientific Officer, and Jeff Schneider Chief Informatics Officer
Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP.
Knock-in mouse models of Huntington’s disease.
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.
PsychoGenics to provide testing services in the R6/2 Mouse Model for Huntington Disease
Discovery of novel hippocampal neurogenic agents by using an in vivo stable isotope labeling technique.
Monitoring brain chemical signals by microdialysis.
Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward.
PsychoGenics Expands Huntington Disease Research Collaboration with High Q Foundation and CHDI
PsychoGenics Appoints Rusiko Bourtchouladze, Ph.D. as Vice President, Cognition and Discovery Research
PsychoGenics Announces Drug Discovery and Development Agreement with Eli Lilly and Company; Companies Will Work Together to Identify New Treatments for Neuropsychiatric Disorders
PsychoGenics, together with the Ewing Marion Kauffman Foundation, sponsors the Translational Research Forum at the BIO 2007 International Convention.
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals
Determination of the dopamine agonist rotigotine in microdialysates from the rat brain by microbore column liquid chromatography with electrochemical detection.
Translational Research Forum to Explore Philanthropy and Drug Development At 2007 BIO International Convention.
Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins.
Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders.
Measurement of cell proliferation by heavy water labeling.
Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery.
Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation.
New methodological aspects of microdialysis.
Use of a platform in an automated open-field to enhance assessment of anxiety-like behaviors in mice.
Netrin-G2 and netrin-G2 ligand are both required for normal auditory responsiveness.
Genetic disruption of both tryptophan hydroxylase genes strongly reduces serotonin in the brain and affects behavior in models sensitive to antidepressants
Standardized Behavioral Test Battery to Identify and Validate Targets for Neuropsychiatric Diseases and Pain.
Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.
Huntington Disease. In Animal and Translational Models of Behavioral Disorders
Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.
PsychoGenics and Roche Enter Agreement to Identify New Treatments for Neuropsychiatric Disorders
Timing Deficits in Neuropathology In Cognitive Aging: Integrating Models.
PsychoGenics Announces Positive Phase-IIa for its First-in-Class Partial 5-HT1A – 5-HT1B Receptor Agonist in ADHD
Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods.
In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity.
Interval timing in genetically modified mice: a simple paradigm.
Learning and memory impairment in Eph receptor A6 knockout mice.
The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects.
Pharmacological manipulations of interval timing using the peak procedure in male C3H mice.
PsychoGenics Appoints John McCall, Ph.D. as Newest Member to its Scientific Advisory Board (SAB)
Interval timing in genetically modified mice: a simple paradigm.
Learning and memory impairment in Eph receptor A6 knockout mice.
Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic.
Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm.
Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal bone development.
GABAa receptor α1 subunit (Gabra1) knockout mice: review and new results. In Mutant and Transgenic Tools in Modeling Brain Disorders
Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models.
Pharmacological characterization of harmaline-induced tremor activity in mice.
The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine.
Behavioural and pharmacological mechanisms of bupropion’s anti-smoking effects: recent preclinical and clinical insights.
Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains.
PsychoGenics Appoints David A. Lowe, as Chief Scientific Officer and Executive Vice President of Research and Development
Acquisition of peak responding
PsychoGenics and AstraZeneca Enter Agreement to Identify New Treatments for Central Nervous System Disorders
Reward-seeking and discrimination deficits displayed by hypodopaminergic mice are prevented in mice lacking dopamine D4 receptors.
Anxiolytic effects of lamotrigine and JZP-4 in the elevated plus maze and in the four plate conflict test.
PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr.
MitoPark mice mirror the slow progression of key Parkinson disease symptoms and the L-DOPA response. Genes, Brain and Behavior
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson’s disease: studies with the P2X(7) receptor antagonist A-438079.
Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. Genes, Brain and Behavior
Comprehensive behavioral testing in the R6/2 mouse model of Huntington’s disease shows no benefit from CoQ10 or minocycline.
The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.
The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments.
Comparison of the predictive validity of the mirror chamber and elevated plus maze tests in mice.
The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.
Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380.
Histopathological and neurological features of Atg4b knockout mice.
PsychoGenics Expands its In Vivo Testing Capabilities with the Addition of Novel Neurogenesis Techniques in Partnership with KineMed Inc.
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington’s Disease.
Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats.
Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone.
Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms.
Impulsive action and impulsive choice are mediated by distinct neuropharmacological substrates in rat
Effect of the rd1 mutation on motor performance in R6/2 and wild type mice [Internet]. Version 28.
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington’s Disease.
PsychoGenics and Evotec Enter into a Strategic Alliance to Provide Integrated CNS Drug Discovery Solutions
Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration,
Discovery of Isoxazole Analogs of Sazetidine-A as Selective alpha4 beta2-Nicotinic Acetylcholine Receptor (nAChR) Partial Agonists for the Treatment of Depression,
HD mouse models reveal clear deficits in learning to perform a simple instrumental response. PLoS Currents: Huntington Disease.
Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms,
Behavior-based screening as an approach to polypharmacological ligands.
PsychoGenics Expands its In Vivo Capabilities with the Addition of Preclinical Magnetic Resonance Imaging Technology Services in Partnership with Ekam Imaging.
PsychoGenics Inc. Announces Positive Efficacy Data in Levodopa Induced Dyskinesia in Parkinson’s Patients.
Caspase-6 activity in a BAC HD mouse modulates steady state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.
R6/2 Huntington’s disease Mice Develop Early and Progressive Abnormal Brain Metabolism and Seizures.
Behavior-Based Screening as an Approach to Polypharmacological Ligands, in Polypharmacology in Drug Discovery.
Identification of Novel alpha4 beta2-Nicotinic Acetylcholine Receptor (nAChR) Agonists Based on an Isoxazole Ether Scaffold that Demonstrate Antidepressant-like Activity. Journal of medicinal chemistry.
Effect of the rd1 mutation on motor performance in R6/2 and wild type mice. PLoS Currents Huntington Disease.
Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Ä7 SMA KO Mouse Model of Spinal Muscular Atrophy.
Afraxis and PsychoGenics Form Alliance to Offer Afraxis’ ESP Technology for Drug Discovery
Prediction of Death in the SMNΔ Mouse Model of Spinal Muscular Atrophy: Insight into Disease Stage and Progression. Journal of Neuroscience Methods.
Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity .
Insights into the Structural Determinants Required for High Affinity Binding of Chiral Cyclopropane-Containing Ligands to α4β2-Nicotinic Acetylcholine Receptors; An Integrated Approach to Behaviorally Active Nicotinic Ligands.
Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175
PsychoGenics Achieves Substantial Milestone in its Drug Discovery Collaboration with Sunovion
Regional vulnerability in Huntington’s disease: fMRI-guided molecular analysis in patients and a mouse model of disease
PsychoGenics and Sunovion Pharmaceuticals Inc. Expand their Drug Discovery Partnership
High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington’s Disease.
PsychoGenics Obtains an Exclusive License to the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease
PsychoGenics Achieves Another Milestone in its Drug Discovery Collaboration with Sunovion
PsychoGenics Receives License to the Cntnap2 Knockout Mouse Model from the Weizmann Institute
Phenotypic characterization of recessive gene knockout rat models of Parkinson’s disease
Genetic Deletion of Transglutaminase 2 Does Not Rescue the Phenotypic Deficits Observed in R6/2 and zQ175 Mouse Models of Huntington’s Disease
Animal Models of Huntington’s Disease for Translation to the Clinic: Best Practices. Movement Disorders
Effect of a novel, orally active matrix metalloproteinease-2 and-9 inhibitor in spinal and trigeminal rat models of neuropathic pain
PsychoGenics Obtains a License to the McGill-R-Thy1-APP Rat Model of Alzheimer’s Disease
PsychoGenics Achieves Another Milestone in Drug Discovery Collaboration with Sunovion
PsychoGenics Obtains a License to α-synuclein Transgenic Mouse Models of Parkinson´s disease
PsychoGenics Obtains a License to Another Transgenic Mouse Model of α-Synucleinopathies
Comprehensive Analysis of the 16p11.2 Deletion and Null Cntnap2 Mouse Models of Autism Spectrum Disorder.
PsychoGenics and the Alzheimer’s Drug Discovery Foundation Announce a Risk-Sharing Partnership for Preclinical Studies
In Vivo Phenotypic Drug Discovery: Applying a Behavioral Assay to the Discovery and Optimization of Novel Antipsychotic Agents. Med. Chem. Commun,.
Large-scale phenome analysis defines a behavioral signature for Huntington’s disease genotype in mice.
Phosphodiesterase 10 inhibition improves cortical – basal ganglia function in Huntington’s Disease models.
Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer
Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
Synergistic antileukemic therapies in NOTCH1-induced T-ALL.
Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer’s Disease
Myelinated axons fail to develop properly in a genetically authentic mouse model of Charcot-Marie-Tooth disease type 2E
Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
Biomarker Analysis of Orally Dosed, Dual Active, Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitor, AQU-118, in the Spinal Nerve Ligation (SNL) Rat Model of Neuropathic Pain
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Actions
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia
PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP)
ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome
Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration
Mouse model systems of autism spectrum disorder: Replicability and informatics signature
Transcriptional Assessment of Striatal mRNAs as Valid Biomarkers of Disease Progression in Three Mouse Models of Huntington’s Disease
PsychoGenics Drug Discovery Featured in Nature Biopharma Dealmakers
PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives
Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex
Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia
Preclinical Mouse Models of Huntington’s Disease at PsychoGenics [WEBINAR]
AI-driven Phenotypic Drug Discovery at PsychoGenics [WEBINAR]
Preclinical Seizure and Epilepsy [WEBINAR]
PsychoGenics Chief Innovation Officer Honored for Scientific Excellence
Molecular Biomarkers and Disease Markers at PsychoGenics [WEBINAR]
Elevation of brain magnesium with Swiss chard and buckwheat extracts in an animal model of reduced magnesium dietary intake
PsychoGenics Appoints Dr. Stephen Morairty as Vice President, Translational Neuroscience and Jean-Sebastien Valois as Vice President, Engineering and AI Development
PsychoGenics’ High Data Security Standards Are Certified by The NIH
Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex
Microglia and the NLRP3 inflammasome pathway contribute to Tau-mediated pathology in vivo
Keystone Symposia
Keystone Resort, Colorado
Authors
Christopher Dumayne, Davide Basco, Alessio Mylonas, Yvan Varisco1, Daniel Havas, Patrick Rodriguez, Francesca Capotosti, Nicolas Fournier, Kasia Piorkowska, Emanuele Gabellieri, Mickaël Audrain, Sonia Poli, Andrea Pfeifer, Marie Kosco-Vilbois and Tamara Seredenina
The NIH HEAL Initiative Preclinical Screening Platform for Pain (PSPP) efforts to validate rodent models of pain and migraine
IASP 2022 World Congress on Pain
Toronto, Canada
Authors
S. Iyengar, S. A. Woller, A.S. Wattiez, M.A. Varney, E. Dugan, C. McDonnell, J. Gresack, E. Leahy, T. Hanania and M. Urban
Efforts to accelerate development of non-opioid, non-addictive pain therapeutics within the NIH HEAL Initiative Preclinical Screening Platform for Pain and validation examples
Advances in Pain
New York, NY
Authors
S. Iyengar, S.A. Woller, E. Dugan, K. Buban, J. Hagedorn, P. Wig, T. Hanania1, M.O. Urban
Characterization of the Rat Monoiodoacetate Model of Osteoarthritis: Evoked and Non-evoked Pain Response Assessments
Advances in Pain
New York, NY
Authors
S. Iyengar, S.A. Woller, E. Dugan, K. Buban, J. Hagedorn, P. Wig, T. Hanania1, M.O. Urban
GBR Connect Series – Interview with Emer Leahy, PsychoGenics
Time course assessment of pathology following bilateral Inoculation of alpha-synuclein preformed fibrils in C57Bl/6 mice
International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)
Barcelona, Spain
Authors
Daniel Havas, Christina Torturo, Kristina Kovacovicova, Romain Migliorini, Nadine Ait-Bouziad, Elpida Tsika, Andrea Pfeifer, Marie Kosco-Vilbois, Sylvie Ramboz
Time course assessment following bilateral and unilateral-dual inoculation of α-synuclein preformed fibrils in C57Bl/6 mice
Neuro4D
Mainz, Germany
Authors
Daniel Havas, Christina Torturo, Smriti Mongia, Kristina Kovacovicova, E. Tsika, Irene Morganstern, Sylvie Ramboz
The NIH HEAL Initiative Preclinical Screening Platform for Pain (PSPP) validation of the monoiodoacetate (MIA) model of osteoarthritis pain in the rat
European Pain Federation (EFIC 2022)
Dublin, Ireland
Authors
S.A. Woller, M.O. Urban, T. Hanania, S. Iyengar
The NIH HEAL Initiative Preclinical Screening Platform for Pain efforts to validate two models of chemotherapy-induced painful neuropathy in the rat
European Pain Federation (EFIC 2022)
Dublin, Ireland
Authors
S. Iyengar M.O. Urban M.A Varney, Taleen Hanania, S.A. Woller
The SmartCube Platform: Use of Phenotypic Screening in Mice with Machine Learning to Identify Novel Antipsychotic Compounds
Schizophrenia International Research Society
Florence, Italy
Authors
M.A. Varney, E. Leahy, A. Ambesi, D. Brunner
Characterization of a model of Parkinson’s Disease using synthetic α-synuclein inoculation to evaluate motor function, synucleinopathy, and dopaminergic neurotransmission
Society for Neuroscience
San Diego, CA
Authors
C. Torturo, K. Cox, R. Peltz, S. Mongia, J. Gresack, D. Havas, D. Budac, S. Ramboz
Characterization of TDP-43 delta NLS mice: behavior and biomarker analyses
Society for Neuroscience
San Diego, CA
Authors
H. B. Fernandes, I. Morganstern, J. Beltran, M. Kwan, J. Shea, A. Ghavami, D. Havas, T. Hanania
Elucidating pain-related activity in the EEG from the rat spinal nerve ligation model (SNL) of neuropathic pain
Society for Neuroscience
San Diego, CA
Authors
L. Devi, D. Brunner, A. Yelisyeyev, A. Aschenbrenner, S.A. Woller, S. Iyengar, S.R. Morairty, S. Leiser
Evaluation of the abuse liability of oxycodone in male and female rats using two approaches: intravenous self-administration and conditioned place preference
Society for Neuroscience
San Diego, CA
Authors
Q. Chang, E.A. Dugan, W. Min, W. Lacsina, P. V. Severino, H. Buechler, D.A. Nicholson, S.A. Woller, S. Iyengar, T. Hanania
Evaluation of behavioral pain phenotype and optimization of the rat paclitaxel and oxaliplatin models of chemotherapy-induced peripheral neuropathy
Society for Neuroscience
San Diego, CA
Authors
T. Hanania, E.A. Dugan, K. Buban, J. Hagedorn, S.A. Woller, S. Iyengar, M.O. Urban
Evaluation of behavioral pain phenotype in the rat monoiodoacetate and medial meniscal tear models of osteoarthritis pain
Society for Neuroscience
San Diego, CA
Authors
M.O. Urban, E.A. Dugan, K. Buban, J. Hagedorn, S.A. Woller, S. Iyengar, T. Hanania
In vivo PK, side effect profile, and efficacy of multiple classes of analgesics in rats
Society for Neuroscience
San Diego, CA
Authors
E. A. Dugan, D. Budac, C. W. McDonnell , M.O. Urban, S.A. Woller, S. Iyengar, T. Hanania, M. Varney
PsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO Capabilities
The CNS drug development drum beat is getting louder
Mental Health Champions: Why & How Dr. Emer Leahy of PsychoGenics Is Helping To Champion Mental Wellness
We need a new Prozac: The demand for brain drug innovation
Industrializing behavioral testing to redefine neuropsychiatric drug discovery
PsychoGenics – Phenotypic Drug Discovery and Preclinical CRO
The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models
Overcoming mental health’s drug development challenges with AI
Emyria teams with CRO PsychoGenics for MDMA-like drug development
Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More
Emyria starts program with neuroscience drug discovery CRO
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
Why Psychogenics and Emyria are collaborating to examine MDMA-inspired compounds
4 next-gen CNS drug development trends
A novel phenotypic approach to CNS drug discovery
Why the TAAR1 agonist ulotaront holds promise for schizophrenia
Optimization and validation of profiling efforts within the NINDS preclinical screening platform for pain (PSPP) to accelerate the development of novel non-opioid, non-addictive pain therapeutics
European Pain Federation (EFIC 2023)
Budapest, Hungry
Authors
S. Iyengar, M. Varnery, M. Urban, E. Dugan, D. Budac, T. Hanania, S. Woller
Elucidating pain-related activity in the EEG from the rat spinal nerve ligation model (SNL) of neuropathic pain
American College of Neuropsychopharmacology (ACNP)
Phoenix, Arizona
Authors
M. Urban, E. Dugan, K. Buban, J. Hagedorn, S. Woller, S. Iyengar and T. Hanania
PsychoGenics CEO explores CNS drug development trends
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD
PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease Day
Phenotypic Profiling of Psychedelics in Mice Using SmartCube to Find the Next Generation of Psychedelic Drug Candidates
The International College of Neuropsychopharmacology (CINP)
Montreal, Canada
Authors
M. Varney, D. Bleakman, A. Pehrson, G. Zhou, A. Ambesi, D. Brunner
Phenotypic Screening of Novel Compounds for Behavioral Aggression in Alzheimer’s Disease
Neuro4D
Mainz, Germany
Authors
M. Varney, D. Bleakman, A. Pehrson, G. Zhou, A. Ambesi, J. Gresack, D. Brunner; T. Hanania,
For More Info Conference Details